FindTrial
Sign In

Alternate-Day Buprenorphine. Phase V - 6

Alternate-Day Buprenorphine. Phase V

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00000224
Enrollment
0
Registered
1999-09-21
Start date
1993-02-28
Completion date
Unknown
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid-Related Disorders

Brief summary

The purpose of this study is to evaluate buprenorphine blockade challenge.

Interventions

DRUGBuprenorphine

Sponsors

University of Vermont
CollaboratorOTHER
National Institute on Drug Abuse (NIDA)
Lead SponsorNIH

Study design

Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
30 Years to 49 Years
Healthy volunteers
No

Inclusion criteria

Please contact site for information.

Design outcomes

Primary

MeasureTime frame
Drug use—
Opioid withdrawal—
Subjective dose estimate—
Drug effect characteristics: ARCI—
Physiological changes in: pupil diameter—
Physiological changes in: blood pressure—
Physiological changes in: heart rate—
Physiological changes in: respiration—
Physiological changes in: bup plasma levels—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026